论文信息 - Strong peak immunogenicity but rapid antibody waning following third vaccine dose in older residents of care homes - 字舞流文

Strong peak immunogenicity but rapid antibody waning following third vaccine dose in older residents of care homes

A. Copas | R. Bruton | S. Gamblin | A. Strange | C. Roustan | A. Hayward | A. Riddell | M. Shrotri | O. Stirrup | Annabel Borg | Scott Warchal | M. Caulfield | R. Beale | L. Shallcross | Jag Kandasamy | N. O'Reilly | Christophe J. Queval | M. Miah | P. Hobson | S. Kjaer | R. Harvey | Rachel Ulferts | Mary Y. Wu | P. Moss | Mahbubur Rahman | K. Ambrose | S. Caidan | Chelsea Sawyer | M. Krutikov | T. Taylor | B. Azmi | N. Kaur | E. Spalkova | P. Sylla | C. Swanton | T. Lancaster | Christopher Bentley | A. Jadir | U. Amin | G. Tut | David Bone | Samuel Hulme | E. Tut’ | C. Fuller | A. Irwin-Singer | V. Baynton | L. Adams | Caitlin Kavanagh | S. Gandhi | Sina Namjou | Mike Gavrielides | B. Clayton | J. Abreu | Emma Russell | Sandeep Sandhar | Neil Bailey | E. Carr | Bobbi Sina Vanessa Meghan Philip Murad Samuel Mauro Tom Clayton Namjou Silva Poulten Bawumia Miah S | Vanessa Silva | Meghan Poulten | Philip Bawumia | Samuel Sade | Mauro Miranda | I. D'Angelo | Titilayo Abiola | Ana Agau-Doce | Mercedes Cabrera Jarana

[1] A. Copas,et al. Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection , 2022, Nature Aging.

[2] J. Haughney,et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial , 2022, The Lancet Infectious Diseases.

[3] T. Chitlaru,et al. T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern , 2022, Viruses.

[4] B. Walker,et al. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals , 2022, Cell.

[5] A. Sette,et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron , 2022, Nature.

[6] G. Iacobucci,et al. Covid-19: Fourth vaccine doses—who needs them and why? , 2022, BMJ.

[7] Ai-Mei Zhou,et al. Omicron variant (B.1.1.529) of SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance , 2022, World journal of clinical cases.

[8] V. Libri,et al. Three-dose vaccination elicits neutralising antibodies against omicron , 2022, The Lancet.

[9] Fei Shao,et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies , 2021, Nature.

[10] Fei Shao,et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies , 2021, bioRxiv.

[11] D. Klonoff,et al. Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics. , 2021, European review for medical and pharmacological sciences.

[12] A. Copas,et al. Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England , 2021, The Lancet Healthy Longevity.

[13] S. Karim,et al. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic , 2021, The Lancet.

[14] A. Copas,et al. Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study , 2021, The Lancet Healthy Longevity.

[15] Frances E. Muldoon,et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 , 2021, Nature.

[16] J. Weiner,et al. Poor antibody response to BioNTech/Pfizer COVID-19 vaccination in SARS-CoV-2 naïve residents of nursing homes , 2021, medRxiv.

[17] A. Copas,et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study , 2021, The Lancet Infectious Diseases.

[18] A. Copas,et al. Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study , 2021, The Lancet Healthy Longevity.

[19] B. Chain,et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose , 2021, Science.

[20] A. Hayward,et al. Spread of a Variant SARS-CoV-2 in Long-Term Care Facilities in England , 2021, The New England journal of medicine.

[21] G. Rait,et al. COVID-19 infection and attributable mortality in UK care homes: cohort study using active surveillance and electronic records (March–June 2020) , 2021, Age and ageing.

[22] C. Swanton,et al. Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains , 2021, bioRxiv.

[23] G. Pawelec,et al. Unanticipated efficacy of SARS-CoV-2 vaccination in older adults , 2021, Immunity & ageing : I & A.

[24] Nguyen H. Tran,et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[25] A. Copas,et al. Reduced Antibody and Cellular Immune Responses Following Dual COVID-19 Vaccination Within Infection-Naïve Residents of Long-Term Care Facilities , 2021, SSRN Electronic Journal.

[26] Vaishali R. Moulton,et al. Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections? , 2021, Frontiers in Physiology.

[27] G. Koh. Faculty Opinions recommendation of Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[28] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[29] G. Rait,et al. Covid-19 infection and attributable mortality in UK Long Term Care Facilities: Cohort study using active surveillance and electronic records (March-June 2020) , 2020, medRxiv.

[30] D. Farber,et al. Human T Cell Development, Localization, and Function throughout Life. , 2018, Immunity.

[31] E. Montecino-Rodriguez,et al. Causes, consequences, and reversal of immune system aging. , 2013, The Journal of clinical investigation.

[32] V. Preedy,et al. Prospective Cohort Study , 2010 .